Knowledge and Intelligence in Drug Design
暂无分享,去创建一个
[1] C. Thornber,et al. Isosterism and molecular modification in drug design , 1979 .
[2] Shawn P Williams,et al. Recent applications of protein crystallography and structure-guided drug design. , 2005, Current opinion in chemical biology.
[3] S. Frantz. Drug discovery: Playing dirty , 2005, Nature.
[4] W. Sneader. Drug prototypes and their exploitation , 1996 .
[5] Bruno Boulanger,et al. A Fast Exchange Algorithm for Designing Focused Libraries in Lead Optimization , 2005, J. Chem. Inf. Model..
[6] J. Tidd,et al. Innovation and Entrepreneurship , 2007 .
[7] Henry S. Rzepa,et al. Chemical Markup, XML, and the World-Wide Web. 3. Toward a Signed Semantic Chemical Web of Trust , 2001, J. Chem. Inf. Comput. Sci..
[8] Alice M. Sapienza,et al. Recognizing, appreciating, and capturing the tacit knowledge of R&D scientists , 2002 .
[9] Alfonso Valencia,et al. Text-mining approaches in molecular biology and biomedicine. , 2005, Drug discovery today.
[10] B. Roth,et al. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .
[11] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[12] John A. Lowe,et al. A guide to drug discovery: The role of the medicinal chemist in drug discovery — then and now , 2004, Nature Reviews Drug Discovery.
[13] A. Barabasi,et al. Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.
[14] William Frawley,et al. Knowledge Discovery in Databases , 1991 .
[15] Kristina Luthman,et al. Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.
[16] Edgar Jacoby,et al. Annotating and mining the ligand-target chemogenomics knowledge space , 2004 .
[17] J. Ashby. Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. , 1985, Environmental mutagenesis.
[18] Henry S Rzepa,et al. Enhancement of the chemical semantic web through the use of InChI identifiers. , 2005, Organic & biomolecular chemistry.
[19] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[20] Sean Ekins,et al. Reengineering the pharmaceutical industry by crash-testing molecules. , 2005, Drug discovery today.
[21] T. Nikolskaya,et al. Biological networks and analysis of experimental data in drug discovery. , 2005, Drug discovery today.
[22] Denis M. Bayada,et al. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.
[23] Victor V. Kryssanov,et al. Understanding design fundamentals: how synthesis and analysis drive creativity, resulting in emergence , 2001, Artif. Intell. Eng..
[24] S. Frye. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.
[25] Stephen Luntz,et al. The Common Thread , 2002 .
[26] Russell L. Ackoff,et al. On purposeful systems , 1972 .
[27] G. Rishton. Reactive compounds and in vitro false positives in HTS , 1997 .
[28] M. Polanyi. Chapter 7 – The Tacit Dimension , 1997 .
[29] Tom L. Blundell,et al. Keynote review: Structural biology and drug discovery , 2005 .
[30] F. Salemme,et al. Chemical genomics as an emerging paradigm for postgenomic drug discovery. , 2003, Pharmacogenomics.
[31] D. Rogers,et al. Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.
[32] Simon M. Tyrrell,et al. Representation and use of chemistry in the global electronic age. , 2004, Organic & biomolecular chemistry.
[33] G. Cruciani,et al. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.
[34] J. Topliss,et al. Utilization of operational schemes for analog synthesis in drug design. , 1972, Journal of medicinal chemistry.
[35] Christopher H. Bryant,et al. Functional genomic hypothesis generation and experimentation by a robot scientist , 2004, Nature.
[36] B. Stockwell. Exploring biology with small organic molecules , 2004, Nature.
[37] Dominic P. Williams,et al. Toxicophores: groups and metabolic routes associated with increased safety risk. , 2002, Current opinion in drug discovery & development.
[38] Michel Dumontier,et al. CO: A chemical ontology for identification of functional groups and semantic comparison of small molecules , 2005, FEBS letters.
[39] A. Hopkins,et al. Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.
[40] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.
[41] A. Fliri,et al. Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] B. Stockwell,et al. Biological mechanism profiling using an annotated compound library. , 2003, Chemistry & biology.
[43] F Darvas,et al. Recent advances in chemical genomics. , 2004, Current medicinal chemistry.
[44] Ruedi Stoop,et al. An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..
[45] T. Ideker,et al. Modeling cellular machinery through biological network comparison , 2006, Nature Biotechnology.
[46] Edgar Jacoby,et al. Chemogenomics knowledge-based strategies in drug discovery. , 2003, Drug news & perspectives.
[47] Kanji Ueda,et al. Synthesis and emergence - research overview , 2001, Artif. Intell. Eng..
[48] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.
[49] Henry S. Rzepa,et al. Chemistry in Bioinformatics , 2005, BMC Bioinformatics.
[50] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[51] T. Baillie,et al. Organic Chemistry in Drug Discovery , 2004, Science.
[52] Stephen H. Muggleton,et al. 2020 Computing: Exceeding human limits , 2006, Nature.
[53] Nikolay P Savchuk,et al. Exploring the chemogenomic knowledge space with annotated chemical libraries. , 2004, Current opinion in chemical biology.
[54] R. Strausberg,et al. From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.
[55] J. Goguen. An introduction to algebraic semiotics, with application to user interface design , 1999 .
[56] I C Parmee. Human-centric intelligent systems for exploration and knowledge discovery. , 2005, The Analyst.
[57] Henry S. Rzepa,et al. Communication and re-use of chemical information in bioscience , 2005, BMC Bioinformatics.
[58] M. Polanyi,et al. Personal Knowledge: Towards a post-critical philosophy , 1959 .
[59] A. Fliri,et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.
[60] A. Fliri,et al. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.
[61] J. Natarajan,et al. Knowledge Discovery in Biology and Biotechnology Texts: A Review of Techniques, Evaluation Strategies, and Applications , 2005, Critical reviews in biotechnology.
[62] Tanja Bekhuis. Conceptual biology, hypothesis discovery, and text mining: Swanson's legacy , 2006, Biomedical digital libraries.
[63] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[64] Michael S Lajiness,et al. Assessment of the consistency of medicinal chemists in reviewing sets of compounds. , 2004, Journal of medicinal chemistry.
[65] Henry S. Rzepa,et al. A global resource for computational chemistry , 2005, Journal of molecular modeling.